Global Breast Cancer Liquid Biopsy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Breast Cancer Liquid Biopsy Market Size

• The global ophthalmic operational microscope market was valued at USD 421.30 million in 2024 and is expected to reach USD 2,220.14 million by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 23.09%, primarily driven by the rising breast cancer prevalence, and advancements in biomarker detection technologies
• This growth is driven by factors such as the rising incidence of breast cancer, advancements in liquid biopsy technology, and growing demand for early cancer detection and personalized medicine

Global Breast Cancer Liquid Biopsy Market Analysis

• The breast cancer liquid biopsy market is witnessing rapid growth, driven by its non-invasive nature and ability to detect cancer at early stages. Liquid biopsies provide real-time insights into tumor progression, making them essential for personalized treatment strategies
• The demand for these tests is significantly driven by the rising incidence of breast cancer, increasing preference for minimally invasive diagnostic methods, and advancements in biomarker detection technologies. Over half of the global demand is fueled by the need for early cancer detection and monitoring treatment efficacy, with the highest demand seen in regions with high cancer prevalence
• The North America region stands out as one of the dominant markets for breast cancer liquid biopsy, supported by its strong healthcare infrastructure, high adoption of precision medicine, and increasing research and development investments

• For instance, the U.S. has witnessed a surge in liquid biopsy adoption, with major healthcare providers integrating these tests into routine oncology care. From leading cancer research institutes to advanced diagnostic laboratories, North America not only utilizes but also drives innovation in liquid biopsy technologies

• Globally, liquid biopsy is emerging as a transformative tool in oncology diagnostics, ranking as one of the most crucial advancements in cancer detection after traditional tissue biopsies. It plays a pivotal role in improving patient outcomes through early detection, treatment monitoring, and therapy selection

Report Scope and Breast Cancer Liquid Biopsy Market Segmentation

Breast Cancer Liquid Biopsy Market Trends

“Advancements in Multi-Gene Panel Testing and AI-Driven Analysis”

• One prominent trend in the global breast cancer liquid biopsy market is the increasing adoption of multi-gene panel testing and AI-driven analysis for enhanced cancer detection and monitoring
• These advancements improve the accuracy and efficiency of liquid biopsies by enabling comprehensive genomic profiling, allowing for the identification of multiple biomarkers in a single test

• For instance, AI-powered algorithms enhance data interpretation by analyzing vast genomic datasets, helping oncologists detect cancer mutations, predict treatment responses, and track disease progression with higher precision

• The integration of AI also facilitates real-time monitoring of tumor evolution, optimizing treatment strategies and reducing the need for invasive tissue biopsies
• This trend is revolutionizing the early detection and management of breast cancer, improving patient outcomes, and driving the demand for innovative liquid biopsy solutions in the market

Breast Cancer Liquid Biopsy Market Dynamics

Driver

“Increasing Demand Due to Rising Breast Cancer Incidence”

• The rising prevalence of breast cancer worldwide is a major factor driving the demand for liquid biopsy tests, which offer a non-invasive and highly accurate method for early detection and disease monitoring
• As breast cancer cases continue to rise, particularly among women aged 50 and older, there is an increasing need for advanced diagnostic tools that can detect cancer at earlier stages and improve treatment outcomes
• Traditional biopsy methods are often invasive, time-consuming, and expensive, whereas liquid biopsies provide real-time insights into tumor evolution, allowing for timely and personalized treatment decisions
• The Ongoing advancements in liquid biopsy technology, such as improved sensitivity in detecting circulating tumor DNA (ctDNA) and integration with next-generation sequencing (NGS), are further enhancing the accuracy and reliability of these tests
• As more healthcare providers and oncologists adopt liquid biopsy for early cancer detection, treatment monitoring, and minimal residual disease (MRD) assessment, the market demand for these tests continues to rise, leading to better patient outcomes and more efficient cancer management

For instance,

• In January 2023, according to an article published by the American Cancer Society, breast cancer remains the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed annually. This growing burden has accelerated the adoption of liquid biopsy for non-invasive detection and monitoring

• In March 2022, according to a study published in the Journal of Clinical Oncology, liquid biopsy has demonstrated significant potential in detecting cancer recurrence months before traditional imaging methods, making it an essential tool for oncologists
• As a result of the rising prevalence of breast cancer and the increasing need for non-invasive diagnostic techniques, there is a significant increase in demand for liquid biopsy solutions in global oncology diagnostics

Opportunity

“Revolutionizing Breast Cancer Diagnosis with AI-Integrated Liquid Biopsy”

• AI-powered liquid biopsy solutions can enhance biomarker detection, automate data interpretation, and improve diagnostic accuracy, enabling oncologists to make more informed decisions in breast cancer management
• AI algorithms can analyze circulating tumor DNA (ctDNA) and other biomarkers in real time, providing instant insights into tumor progression, treatment response, and minimal residual disease (MRD) detection
• In addition, AI-integrated liquid biopsy platforms can assist in large-scale genomic data analysis, enabling oncologists to identify mutations, predict therapy resistance, and personalize treatment plans more effectively

For instance,

• In February 2024, according to an article published in Nature Medicine, AI-driven liquid biopsy technologies demonstrated a higher accuracy rate in detecting early-stage breast cancer compared to traditional methods, significantly reducing false positives and negatives. The study highlighted AI’s role in improving early detection and patient stratification for targeted therapies
• In October 2023, according to research published in the Journal of Clinical Oncology, AI-enhanced liquid biopsy models were shown to predict breast cancer recurrence up to six months earlier than conventional imaging techniques, allowing for timely therapeutic interventions and better disease management

• The integration of AI in liquid biopsy technology can lead to earlier cancer detection, optimized treatment strategies, and improved patient survival rates. By leveraging AI-driven biomarker analysis, oncologists can enhance precision medicine approaches, reduce unnecessary treatments, and improve overall cancer care outcome

Restraint/Challenge

“High Equipment Costs Hindering Market Penetration”

• The high cost of breast cancer liquid biopsy tests poses a significant challenge for the market, particularly impacting their adoption in low and middle-income regions where healthcare budgets are limited
• These Liquid biopsy tests, which offer a non-invasive and highly accurate method for cancer detection and monitoring, can often range from several hundred to thousands of dollars per test, depending on the complexity and the number of biomarkers analyzed
• This substantial financial burden can deter healthcare providers and patients from opting for liquid biopsy over traditional tissue biopsy methods, limiting its accessibility and widespread adoption

For instance,

• In October 2024, according to an article published by the Journal of Precision Oncology, one of the primary concerns surrounding liquid biopsy adoption is its high cost, which may not be fully covered by insurance in several countries. This financial constraint limits access to advanced cancer diagnostics, particularly in resource-constrained healthcare systems

• Consequently, such cost barriers can result in disparities in early cancer detection, restricting access to precision oncology treatments and hindering the overall growth of the breast cancer liquid biopsy market

Breast Cancer Liquid Biopsy Market Scope

The market is segmented on the basis of product, circulating biomarkers, and end users

Breast Cancer Liquid Biopsy Market Regional Analysis

“North America is the Dominant Region in the Breast Cancer Liquid Biopsy Market”

• North America dominates the breast cancer liquid biopsy market, driven by advanced healthcare infrastructure, high adoption of precision oncology solutions, and the strong presence of leading biotech and diagnostic companies
• The U.S. holds a significant share due to increasing breast cancer incidence, rising preference for non-invasive diagnostic methods, and strong regulatory support for liquid biopsy innovations
• The availability of well-established reimbursement policies, extensive research & development investments, and rapid advancements in next-generation sequencing (NGS) and AI-driven diagnostics further strengthen the market
• In addition, the widespread availability of clinical trials and the growing demand for personalized medicine are fueling market expansion across the region

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• The Asia-Pacific region is expected to witness the highest growth rate in the breast cancer liquid biopsy market, driven by improving healthcare infrastructure, increasing cancer awareness, and rising adoption of advanced diagnostic technologies
• Countries such as China, India, and Japan are emerging as key markets due to the rising breast cancer burden, growing emphasis on early detection, and expanding healthcare investments
• Japan, with its technological advancements in oncology diagnostics and increasing focus on precision medicine, remains a crucial market for liquid biopsy solutions, leading in the integration of AI-driven biomarker analysis
• China and India, with their large populations and rising cases of vision-related disorders, are witnessing increased government and private sector investments in modern ophthalmic surgical setups. The expanding presence of global medical device manufacturers and improving accessibility to advanced ophthalmic care further contribute to market growth

Breast Cancer Liquid Biopsy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• Agilent Technologies Inc. (U.S.)
• Merck KGaA (Germany)
• QIAGEN (Germany)
• Abcam plc. (U.K.)
• Cell Signaling Technology Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• The Menarini Group (Italy)
• Genomic Health (U.S.)
• Johnson & Johnson Private Limited. (U.S.)
• Medtronic (Ireland)
• Siemens Healthineers (Germany)
• Biocept, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Fluxion Biosciences, Inc. (U.S.)
• FOUNDATION MEDICINE, INC. (U.S.)
• Sysmex Inostics Inc. (U.S.)
• ExoDx (U.S.)
• Illumina, Inc. (U.S.)

Latest Developments in Global Breast Cancer Liquid Biopsy Market

• In January 2025, The NHS in England began offering liquid biopsies to women with mutated breast cancer, facilitating access to new life-extending treatments designed to target specific genetic mutations. This advancement allows for real-time monitoring of tumor evolution and treatment resistance, marking a significant step forward in precision medicine for breast cancer patients
• In October 2024, The U.K. government announced funding for a £120 blood test capable of detecting 12 common cancers, including breast cancer, before symptoms appear. Developed by researchers at the University of Southampton, this PCR-based test aims to revolutionize early cancer detection and treatment, potentially improving survival rates through earlier intervention
• In November 2024, Illumina, Inc. launched version 2 of the TruSight Oncology 500 ctDNA kit, enhancing the precision of genomic profiling for solid tumors, including breast cancer. This updated assay offers faster results with improved analytical sensitivity, aiding in the detection of drug resistance and monitoring of tumor progression
• In December 2024, Guardant Health, Inc. partnered with Susan G. Komen to develop clinical studies aimed at identifying early-stage breast cancer patients using Guardant Reveal, a blood-based test. This collaboration focuses on improving early detection and personalized treatment strategies for breast cancer patients

SKU-24522